Compare PAYO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYO | LQDA |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | N/A | 2018 |
| Metric | PAYO | LQDA |
|---|---|---|
| Price | $5.68 | $33.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $9.79 | ★ $37.40 |
| AVG Volume (30 Days) | ★ 2.8M | 2.0M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,039,820,000.00 | $69,216,000.00 |
| Revenue This Year | $11.18 | $904.79 |
| Revenue Next Year | $7.45 | $188.25 |
| P/E Ratio | $31.18 | ★ N/A |
| Revenue Growth | 10.58 | ★ 343.41 |
| 52 Week Low | $4.92 | $10.37 |
| 52 Week High | $11.19 | $34.02 |
| Indicator | PAYO | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 69.52 |
| Support Level | $5.65 | $30.50 |
| Resistance Level | $5.87 | $32.80 |
| Average True Range (ATR) | 0.17 | 1.82 |
| MACD | 0.04 | 0.31 |
| Stochastic Oscillator | 65.74 | 99.22 |
Payoneer Global Inc is a financial technology company purpose-built to enable the world's small and medium-sized businesses (SMB(s)) to grow and operate their businesses around the world by reliably and securely connecting them to the digital economy. The company started to empower commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.